Why Talkspace’s sale to Universal Health Services is actually a ‘modest win’ for the health-tech industry

This week, Talkspace announced it has entered an agreement to be acquired by Universal Health Services for $835 million, marking the first public ripple in our projected wave of 2026 digital health acquisitions. The deal represents a ~10% premium to TALK’s prior close, and is a reminder that, despite recent public investor sentiment, telemedicine remains a valuable tool in the toolbox for healthcare services incumbents to both acquire and maintain their patient relationships. 

Universal Health Services or UHS — not to be confused with United — is a hospital and healthcare services company with over 100,000 employees. It operates emergency departments, acute care hospitals, behavioral health inpatient facilities, outpatient facilities, and ambulatory care centers, according to its website.

Here’s a few of our thoughts as an investor and former journalist (Chrissy) and equity research analyst (Stephanie). Both of us covered the various twists and turns of Talkspace in our former lives, so we immediately started texting as soon as the deal got announced. And that series of messages resulted in this analysis.

Talkspace accelerates UHS’s virtual strategy

For Universal Health Services, the strategic value is clear: (1) an accelerant of the virtual strategy, (2) access to virtual therapists for the outpatient business, (3) bi-directional referral channels, and (4) expanded payer relationships. 

Historically, UHS has had a very low percentage of virtual engagement, with telemedicine mainly being used to supplement staffing needs at inpatient facilities. This has been a limiter of UHS’s “step down” discharge offering, as the outpatient business necessitated continued in-person care. TALK would allow UHS to provide a more flexible virtual solution that could not only garner higher engagement but could be especially important for the company’s younger demographics (ie, the teenage population). While UHS could have developed their own virtual outpatient program, the pace of therapist recruitment tends to be a limiter; with the deal, TALK brings 6k therapists (albeit mostly 1099 vs. W2) 

More than a funnel for step-down referrals, Talkspace can also refer its patient population that may be in need of more intensive or in-person care to UHS as its partner. Universal Health Services tends to see patients with higher acuity behavioral health conditions, while Talkspace focuses on what it can treat online (anxiety, depression, and so on). There is some overlap here – conditions like OCD and anorexia have been treated successfully through virtual treatment modalities. But overall, a Talkspace patient could get routed to outpatient or inpatient treatment via Universal Health Services, depending on their level of need. That provides a patient recruitment mechanism on both sides.

Depending on how creative UHS gets with its patient interactions, there are future opportunities as well. As a virtual behavioral health player, Talkspace could serve as a virtual front door for behavioral health patients. At the macro level, payers have been pushing back more on rates for therapy, with visit volumes exploding in the years since the pandemic. It’s impossible to open up a social media app these days without a company pushing therapy. Insurers don’t look kindly upon behavioral health companies that push therapy for extended periods on people who may not need it. But they also know that virtual care is measurable, and that there are ways to prevent extremely expensive episodes with early treatment. This partnership could be well-positioned to hold the line on rates, because patients could be more seamlessly moved between modalities depending on their level of acuity. 

UHS also highlighted strengthened payer relationships, which reflect positively on TALK CEO Jon Cohen's pivot when joining, taking TALK from its D2C roots into a B2B business. The company has courted contracts with state and local governments, employers, and, notably, the military, with UHS highlighting the TRICARE contract. Through these partnerships, more than 200 million people now have access to Talkspace through their insurance. 

Valuation healthy for the sector

The deal makes a lot of sense in terms of the strategy. But there’s also a story to tell by looking at the numbers. 

The basics:

• Revenue (consensus): $280M in CY26, $340M in CY27 
• Purchase price / EV: $5.25 per share / ~$835M
• Prior close pre-deal: $4.76 per share / ~$788M market cap

The deal represents a 10% premium to TALK’s prior close, which, while slim vs. a more normalized 20% takeout premium, comes on the heels of a 60%+ run over the past 12 months. 

How healthy is that premium - and what does it mean for the health-tech industry at large?

Well, TALK’s takeout multiple of ~3.0x revenues actually represents a fairly healthy premium to the recent digital health average (recall ACCD was taken out at ~1x).

By comparison, this is in line to slightly below pre-COVID valuations. However, similar to many of the virtual care companies that have exited recently, returns would not have been stellar for private market investors, particularly at the growth stages. Talkspace announced a reverse merger, giving it a $1.4 billion valuation in 2021, following $110 million from investors, including Softbank. In the pandemic, the private markets threw down crazy valuations for virtual care/tech-enabled services companies (in the 10x to 20x revenue multiple range). Even in the best-case scenario, late-stage investors lost their shirts as these companies have now exited. 

Persisting disconnect in market views vs. actual utilization 

From a valuation perspective, this takeout reflects a persistent disconnect between public virtual care valuations and real-world patient utilization. Ironically, investors assigned a higher valuation to telehealth businesses in a pre-COVID environment vs. today– using TDOC as an example, valuations collapsed from ~5x revenues to ~1x.. Looking at the pandemic, Teladoc has lost 80 to 90% from its peak, Amwell is down close to 95%, and many of the SPAC digital health companies have collapsed. And yet, telehealth usage has exploded in the years since the pandemic. 

Reimbursement has become far more favorable for virtual visits versus in-office visits, and patients are far more used to seeing doctors online. Providers are also comfortable with it. We have seen a tripling of telemedicine usage, per the American Medical Association. Among the public companies, we have seen a sizable ramp in utilization: even the best virtual care utilization rates in a pre-pandemic era ranged in the low to mid single digits, vs a healthy double-digit rate today. And behavioral health providers are amongst the most comfortable with it, versus other specialties. 

So on the face of it, that doesn’t make much sense. Why is usage so much higher but valuations have returned to pre-Covid levels? Well, a few thoughts from us to explain what public market investors might be thinking:

• 2021-2022 was an outlier: What were we all thinking? Valuations in the private markets just didn’t line up with reality. 20x revenue multiples should not have been justified for services businesses because it’s so far off the public markets. 
• Telemedicine has its challenges, and the market is now seeing that clearly. There’s a finite pool of providers, and as markets get more competitive, salaries only go up. That hurts margins. 
• Insurers can pushback on rates or stop giving favorable rates to venture-backed companies if they’re not exercising clinical judgment and measuring outcomes. 
• It is very expensive to market to patients unless the company has some kind of unique referral strategy or edge. 
• Virtual care is not a panacea: Visits have started to stabilize as patients and providers are realizing there’s still a need to be seen in person for certain procedures. Behavioral health might have the strongest argument for virtual, and yet there are patients who value sitting face-to-face from their provider or need to be in inpatient facilities. 

Many of the care delivery players funded by VCs were destined for consolidation. They were more strategically valuable as a front door to a hospital system, or a consumer-facing navigation platform for a payer. But it has taken many years for that to play out in the market because of the disconnect between private market and public market valuations. If a VC pays a 20x revenue multiple for a company, they are incentivized to push that company to operate for longer in the private markets to swing for the fences. That might mean saying no to reasonable offers on the table, which might have represented the most ideal outcome for the business. 

Takeaways for other Digital Health players

The subtext of this acquisition is that while D2C models make for a great proof of concept in the market, B2B business models still represent the only reliable onramp to the broader healthcare services universe. TALK’s journey from an $0.80 per share D2C virtual behavioral health company to a $5.25 per share B2B company reflects this, while the growth drag created by a slow B2B pivot for Teladoc’s BetterHelp serves as another proof point. 

Beyond purely creating exit opportunities, the shift to B2B also substantially brings down the customer acquisition cost for patients (even if marketing costs are still high to ensure patients actually use the service) as well as increases LTV (no surprise, patients tend to utilize a service for longer if they’re not paying out of pocket). In a difficult macroeconomic tape and compressed purchasing power, D2C models may represent a relic of bull markets’ past. 

So is this a win for Talkspace/UHS?

Given the state of the public digital health tape, a successful takeout represents a win, if a modest one, vs. pandemic highs. While the market has not rewarded UHS– the stock was down as much as 4% today on the news– Talkspace is clearly strategically extremely useful to its acquirer, and this is a unique moment to buy it at a price that makes sense. 

The acquisition premium is slim, but investors still must have believed that Talkspace has steady growth potential (consensus projections represented 20%+), with minimal margin expansion (so the AI story might not have been taken into account). This is also a win for Talkspace as it faced clinician shortages, reimbursement challenges, marketing costs, and a volatile market. With Universal Health Services, it has a strong referral relationship, and it will be integrated into a much bigger care delivery network. That’s a much more stable operating environment. 

But the valuation (and availability of virtual behavioral health assets for sale) also suggests there might not have been a bidding war, potentially reflecting some of the known challenges with behavioral health. And yet the public/private market disconnect persists: a few weeks ago, the market valued another BH player, Grow Therapy, at $3 billion. NOCD, Charlie Health, Brightline, and Equip Health have also continued to attract investment dollars, particularly given their focus on higher acuity patients. So what’s the winning playbook here in behavioral health? Stay tuned for more analysis from us, and we’d welcome your feedback and contributions! 

Want to support Second Opinion?

• 🌟 Leave a review for the Second Opinion Podcast
• 📧 Share this email with other friends in the healthcare space!
• 💵 Become a paid subscriber!
• 📢 Become a sponsor